Tuesday, 16 Oct 2018

You are here

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.

At month 4, a 30% improvement on the criteria of the American College of Rheumatology (ACR30) was seen in 83.2% of a group of children ages 6 to 17 years (cohort 1) and in 89.1% of those ages 2 to 5 years (cohort 2), according to Hermine I. Brunner, MD, of Cincinnati Children's Hospital Medical Center, and colleagues.

And at month 24, ACR30 responses were observed in 58% and 100% of patients in cohorts 1 and 2, respectively, the researchers reported online in Arthritis & Rheumatology.

The usual first-line disease-modifying antirheumatic drug treatment in JIA is methotrexate. If disease persists after 3 months, a biologic -- usually a tumor necrosis factor (TNF) inhibitor -- typically is started.

However, multiple treatment options are necessary, as not all patients respond to methotrexate or TNF inhibitors.

Intravenous abatacept has demonstrated efficacy for adult rheumatoid arthritis and for JIA in children ages 6 to 17 years, but the safety and efficacy of the subcutaneous formulation in JIA has not previously been established.

Therefore, the Pediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group initiated an international study in 2013, enrolling children with any subtype of polyarticular JIA from 48 centers.

Part 1 of the study consisted of 4 months of open-label abatacept given weekly in a weight-based manner, with children 10 to 25 kg receiving 50 mg, those 25 to 50 kg being given 87.5 mg, and those 50 kg and higher receiving 125 mg.

Part 2 of the study was a 20-month extension using the same dosing regimen for children who were ACR30 responders at month 4.

A total of 173 patients in cohort 1 and 46 in cohort 2 entered part 1 of the study, with 76.3% and 52.2%, respectively, completing the full 24 months.

In cohort 1, median age was 13 years, 79% were female, and median disease duration was 2 years. Median number of active joints was 10, and median number of joints with limited range of motion was eight. Median physician global assessment was 48, and median parental global assessment was 47.8.

In cohort 2, median age was 4 years, 61% were female, and median disease duration was 0.5 years. Number of active and limited joints were seven and eight, respectively, and physician and parent global assessments were 50 and 42.1.

At baseline, 78.6% of those in cohort 1 and 80.4% of those in cohort 2 were receiving methotrexate, while 32.4% and 19.6% were using oral steroids. Prior biologic use was reported in 26.6% and 21.7%.

The median steady state serum trough concentration of abatacept at month 4 was above the target therapeutic level of 10 µg/mL in both groups. For cohort 1, the median trough concentration was 40.5 µg/mL, and for cohort 2, the median concentration was 51.2 µg/mL.

Clinical improvements were apparent in both groups by month 1, increasing through month 21, the investigators noted.

More stringent improvements of 50%, 70%, 90%, and 100% responses at month 4 were observed in 72.8%, 52.6%, 28.3%, and 14.5% of cohort 1, and in 84.8%, 73.9%, 58.7%, and 41.3% of cohort 2, respectively. By month 24, low disease activity was observed in 42.8% and 90.9% of the two groups.

With regard to safety, serious adverse events were reported in 8.1% of cohort 1 and in 6.5% of cohort 2, with two events being considered related to treatment (one sepsis, one overdose). In cohort 1 there also was one malignancy considered unrelated, and three autoimmune disorders, also considered unrelated.

Infections occurred in 68.2% of patients in cohort 1 and in 78.3% of those in cohort 2. These rates were higher than what has been seen among adults with rheumatoid arthritis receiving abatacept, but this finding was expected because of the recognized greater susceptibility of children to infection, the authors noted.

Injection site reactions were observed in 6.9% and 4.3% of cohorts 1 and 2, respectively. Most were mild.

Antibodies to abatacept developed in 2.3% and 8.7% of patients in cohorts 1 and 2, respectively, but were transient and did not appear to affect efficacy or safety.

Abatacept is not commonly used early in the course of JIA treatment. However, "the results from cohort 2 reported here, in which abatacept treatment was initiated in patients with a median disease duration of only 0.5 years, provide valuable data on the early introduction of abatacept; notably, JIA-ACR response rates were consistently higher in cohort 2 than in cohort 1," Brunner and colleagues wrote.

A limitation of the study was its open-label design.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.